RADXRadiopharm Theranostics, LtdSigning up patients
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
Castration-resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 73 (planned)
- Started
- Mar 5, 2026
- Main results expected
- Nov 30, 2028
- Fully finished
- Mar 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of treatment emergent adverse events of 161Tb RAD402 (phase 1) (Safety)
Measured over: 6 weeks
Recommended dose(s) of 161Tb RAD402 for future exploration (phase 1)
Measured over: 6 weeks
Preliminary anti-tumor activity, as defined by biochemical response, in participants who are treated with 161Tb RAD402 at the RP2D (phase 2a)
Measured over: Up to 30 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07259213 · record last updated 2026-04-01 · checked 2026-11-09 15:47 UTC